Biogen Acquires Apellis Pharmaceuticals for $5.6B

Biogen has entered into a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion. This strategic acquisition is set to significantly bolster Biogen's presence in the immunology and rare-disease therapeutic areas. The move is expected to enhance Biogen's drug pipeline and market position, particularly in areas with high unmet medical needs. Investors will be closely watching the integration process and the potential for these newly acquired assets to drive future growth and profitability for Biogen.